Baron Silver Stevens Financial Advisors, LLC Bristol Myers Squibb CO Transaction History

Baron Silver Stevens Financial Advisors, LLC

$527 Million
Q2 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	SELL	$57.89 - $64.73 $10,941 - $12,233	-189 Reduced 4.98%	3,603 $209,000
Q2 2023 Jul 24, 2023	SELL	$63.71 - $70.74 $12,550 - $13,935	-197 Reduced 4.94%	3,792 $242,000
Q1 2023 Apr 18, 2023	SELL	$65.71 - $74.53 $26,152 - $29,662	-398 Reduced 9.07%	3,989 $276,000
Q4 2022 Jan 30, 2023	BUY	$68.48 - $81.09 $300,421 - $355,741	4,387 New	4,387 $315,000
Q2 2022 Jul 26, 2022	BUY	$72.62 - $79.98 $16,557 - $18,235	228 Added 5.55%	4,333 $333,000
Q1 2022 May 03, 2022	BUY	$61.48 - $73.72 $122 - $147	2 Added 0.05%	4,105 $299,000
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $14,970 - $17,535	-253 Reduced 5.81%	4,103 $242,000
Q2 2021 Jul 27, 2021	BUY	$61.91 - $67.42 $30,273 - $32,968	489 Added 12.65%	4,356 $291,000
Q1 2021 Apr 27, 2021	BUY	$59.34 - $66.74 $60,526 - $68,074	1,020 Added 35.83%	3,867 $244,000
Q4 2020 Mar 19, 2021	BUY	$57.74 - $65.43 $164,385 - $186,279	2,847 New	2,847 $176,000

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

Vanguard Group Inc Valley Forge, PA

187M
Shares

$9.92 Billion
0.15% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$8.44 Billion
0.15% of portfolio
State Street Corp Boston, MA

91.4M
Shares

$4.86 Billion
0.17% of portfolio
Jpmorgan Chase & CO New York, NY

74.6M
Shares

$3.97 Billion
0.27% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

59.1M
Shares

$3.14 Billion
0.47% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baron Silver Stevens Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baron Silver Stevens Financial Advisors, LLC with notifications on news.

Account